300601 Shenzhen Kangtai Biological Products
- 16.73
- -0.37-2.16%
Shenzhen Kangtai Biological Products News
Shenzhen Kangtai Biological Products (300601.SZ) has developed some products using synthetic biology-related technology platforms.
Kangtai Biological (300601.SZ) stated on the investor interaction platform on June 7th that the development of some of the company's products involves synthetic biology-related technology platforms, such as recombinant hepatitis B vaccines; and the development of new synthetic biology products such as respiratory syncytial virus (RSV) vaccines, herpes zoster vaccines, etc. is being pushed forward as planned.
Shenzhen Kangtai Biological Products (300601.SZ) will distribute 10 bonus shares and 2 yuan per share for the 2023 equity, with a registration date of June 13.
Kangtai Biological Products (300601.SZ) announced on June 5th that the company's annual equity distribution plan for 2023 is as follows: based on the total share capital on the day of equity registration determined in the announcement of the implementation of the annual equity distribution in 2023, the company will distribute cash dividends (including tax) of RMB 2.000000 per 10 shares to all shareholders from undistributed profits. The equity registration date for this distribution is June 13, 2024, and the ex-rights and ex-dividend date is June 14, 2024.
Is The Market Rewarding Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Shenzhen Kangtai Biological Products (SZSE:300601) has had a rough three months with its share price down 21%. It is possible that the markets have ignored the company's differing financials and dec
Kangtai Biology (300601.SZ): The quadrivalent influenza virus lysis vaccine added clinical trial applications for people aged 6-35 months were accepted
Gelonghui, May 20, 丨 Kangtai Biotech (300601.SZ) announced that the company recently received an acceptance notice issued by the State Drug Administration, agreeing to accept clinical trial applications for the quadrivalent influenza virus lysis vaccine developed by the company in people aged 6-35 months. The company's quadrivalent influenza virus lysis vaccine (for people aged 3 years and above) is currently in phase I and III clinical trials. The current clinical trial application for the company's quadrivalent influenza virus lysis vaccine for people aged 6-35 months has been accepted. The quadrivalent influenza virus lysis vaccine can stimulate the body to develop immunity against the influenza virus and is used to prevent vaccine-related influenza diseases
Impressive Earnings May Not Tell The Whole Story For Shenzhen Kangtai Biological Products (SZSE:300601)
Unsurprisingly, Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) stock price was strong on the back of its healthy earnings report. However, we think that shareholders may be missing so
Market Participants Recognise Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) Earnings
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 29x, you may consider Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) as a stock to avoid entire
Kangtai Biology (300601.SZ): Live attenuated chickenpox vaccine obtained drug registration certificate
Gelonghui, April 16 | Kangtai Biotech (300601.SZ) announced that Beijing Minhai Biotechnology Co., Ltd. (“Minhai Biotech”), a wholly-owned subsidiary of the company, received a “Drug Registration Certificate” for the live attenuated chickenpox vaccine issued by the State Drug Administration today. The live attenuated varicella vaccine is made by inoculating human diploid cells with chickenpox zoster virus, cultivating, harvesting viral solution, and freeze-drying with an appropriate stabilizer. The vaccine is suitable for healthy people over the age of 12 months who are susceptible to chickenpox. After vaccination, it can stimulate the body to develop immunity against varicella-zoster virus and is used to prevent chickenpox. Chickenpox spreads through the respiratory tract
Kangtai Biotech (300601.SZ): Sabin strain polio inactivated vaccine (Vero cell) application for production registration accepted
Gelonghui, April 11 | Kangtai Biology (300601.SZ) announced that the Sabin strain polio inactivated vaccine (Vero cell) developed by Beijing Minhai Biotechnology Co., Ltd. (“Minhai Biology”), a wholly-owned subsidiary of the company, applied for production registration and obtained a “Notice of Acceptance” issued by the State Drug Administration, with acceptance number: CXSS2400041. Sabin polio inactivated vaccine (Vero cells) is used to prevent acute infectious diseases caused by the polio virus. After receiving the Sabin strain polio inactivated vaccine (Vero cells), it can stimulate
Kangtai Biotech (300601.SZ): Oral live attenuated pentavalent rotavirus vaccine (Vero cells) begins phase II clinical trial
Gelonghui, April 1, 丨 Kangtai Biology (300601.SZ) announced that the oral pentavalent recombinant rotavirus live vaccine (Vero cell) developed by the company and its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd. (“Minhai Biology”) has completed preparations for phase II clinical trials, started phase II clinical trials, and recently successfully completed the first case of the subject. The oral pentavalent rotavirus attenuated live vaccine (Vero cells) is suitable for infants aged 6 to 32 weeks to prevent infant gastroenteritis caused by rotavirus infection. This product contains the main viral blood of gastroenteritis caused by rotavirus in China
Kangtai Biotech (300601.SZ): Minhai Biotech held a signing ceremony for the “Strategic Cooperation Memorandum” with the Daxing District Government and AstraZeneca
Gelonghui, March 26, 丨 Kangtai Biotech (300601.SZ) announced that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd. (“Minhai Biotech”), the Beijing Daxing District People's Government (“Daxing District Government”) and AstraZeneca Investment (China) Co., Ltd. (“AstraZeneca”) held a signing ceremony for the “Strategic Cooperation Memorandum” on March 25, 2024. According to national laws and regulations and subject to internal approval by all parties, on the basis of full consultation, all parties are willing to jointly explore opportunities to establish strategic partnerships and gradually explore all-round cooperation in the following areas: Joint exploration
These 4 Measures Indicate That Shenzhen Kangtai Biological Products (SZSE:300601) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Owning 48% in Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) Means That Insiders Are Heavily Invested in the Company's Future
Key Insights Insiders appear to have a vested interest in Shenzhen Kangtai Biological Products' growth, as seen by their sizeable ownership A total of 5 investors have a majority stake in the compan
Kangtai Biotech (300601.SZ): Adsorbed tetanus vaccine begins phase I clinical trial
Gelonghui, March 1 | Kangtai Biology (300601.SZ) announced that the adsorbed tetanus vaccine developed by Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as “Minhai Biology”), a wholly-owned subsidiary of the company, has completed preparations for phase I clinical trials, officially started phase I clinical trials, and successfully completed the first patient enrollment today. Adsorbed tetanus vaccine is a vaccine prepared using tetanus toxoid adsorption with adjuvants. This vaccine is suitable for people who are more likely to be traumatized. Pregnant women can get this product to prevent maternal and neonatal tetanus. After receiving this vaccine, it can stimulate the body to produce tetanus antibodies and prevent tetanus.
Are Poor Financial Prospects Dragging Down Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601 Stock?
Shenzhen Kangtai Biological Products (SZSE:300601) has had a rough three months with its share price down 22%. Given that stock prices are usually driven by a company's fundamentals over the long te
Kangtai Biology (300601.SZ): The self-developed live attenuated varicella vaccine has completed on-site registration verification and GMP compliance inspection
Gelonghui, Feb. 8: Kangtai Biotech (300601.SZ) said on the investor interactive platform that the company has laid out a rich pipeline and is steadily advancing the R&D process and industrialization of products under development. Up to now, the company has more than 30 research projects, of which 16 have entered the registration process. The live attenuated varicella vaccine independently developed by the company has completed registration site verification and GMP compliance testing; the Sabin strain polio inactivated vaccine (Vero cell) has obtained a phase III clinical trial summary report; the adsorbed acell-free leukocytosis (component) combination vaccine has completed basic phase I clinical exemption
Kangtai Biotech (300601.SZ): Actual controller Du Weimin pledges additional 5.83 million shares
Gelonghui, February 8, 丨 Kangtai Biotech (300601.SZ) announced that the company received a notice from Mr. Du Weimin, the controlling shareholder and actual controller of the company, and learned that Mr. Du Weimin has applied for supplementary pledge business for some of the company's shares. The total number of shares pledged this time is 5.83 million shares.
Kangtai Biology (300601.SZ): Plans to donate 10.366 million yuan to the China Hepatitis Prevention Foundation
Gelonghui, January 31 | Kangtai Biotech (300601.SZ) announced that in order to support the development of public health and national health, the company plans to donate RMB 10.366 million (over three years) to the China Hepatitis Prevention and Control Foundation for the protection of families infected with hepatitis B virus initiated by the China Hepatitis Prevention and Control Foundation.
Kangtai Biotech (300601.SZ): Minhai Biotech's 20-valent pneumococcal polysaccharide conjugate vaccine application accepted
Gelonghui, January 23 | Kangtai Biotech (300601.SZ) announced that Beijing Minhai Biotechnology Co., Ltd. (“Minhai Biotech”), a wholly-owned subsidiary of the company, recently received an acceptance notice issued by the State Drug Administration and agreed to accept the clinical trial application for the 20-valent pneumococcal polysaccharide conjugate vaccine developed by Minhai Biotech. The 20-valent pneumococcal polysaccharide conjugate vaccine is suitable for infants and children aged 2 months to 5 years. After receiving this vaccine, the body can produce an immune response to prevent invasive diseases caused by 20 pneumococcal serotypes (including bacteremic pneumonia, meningitis, sepsis, and bacteremia
The Three-year Shareholder Returns and Company Earnings Persist Lower as Shenzhen Kangtai Biological Products (SZSE:300601) Stock Falls a Further 4.4% in Past Week
As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of Shenzhen Kang
Kangtai Biological Forecasts Swing to Profit in 2023
Shenzhen Kangtai Biological Products (SHE:300601) expects to return to profit in 2023, driven by an anticipated 16% increase in revenue. Net profit in 2023 is predicted to have ranged between 850 mill
Analysis
Price Target
No Data
